| Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer L Mezquita, E Auclin, R Ferrara, M Charrier, J Remon, D Planchard, ... JAMA oncology 4 (3), 351-357, 2018 | 760 | 2018 |
| Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC B Besse, M Charrier, V Lapierre, E Dansin, O Lantz, D Planchard, ... Oncoimmunology 5 (4), e1071008, 2016 | 729 | 2016 |
| Dendritic cell–derived exosomes as immunotherapies in the fight against cancer JM Pitt, M Charrier, S Viaud, F André, B Besse, N Chaput, L Zitvogel The Journal of Immunology 193 (3), 1006-1011, 2014 | 307 | 2014 |
| Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathologic entities. C Coutzac, J Adam, E Soularue, M Collins, A Racine, C Mussini, L Boselli, ... Journal of Crohn's and Colitis, 2017 | 145 | 2017 |
| Circulating innate immune markers and outcomes in treatment-naïve advanced non–small cell lung cancer patients M Charrier, L Mezquita, B Lueza, L Dupraz, D Planchard, J Remon, ... European Journal of Cancer 108, 88-96, 2019 | 43 | 2019 |
| Quantitation of human herpesvirus-6A,-6B and-7 DNAs in whole blood, mononuclear and polymorphonuclear cell fractions from healthy blood donors B Géraudie, M Charrier, P Bonnafous, D Heurté, M Desmonet, ... Journal of clinical virology 53 (2), 151-155, 2012 | 40 | 2012 |
| Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics L Mezquita, I Preeshagul, E Auclin, D Saravia, L Hendriks, H Rizvi, ... European Journal of Cancer 151, 211-220, 2021 | 38 | 2021 |
| IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: Implications for antimetastatic treatment M Desbois, C Béal, M Charrier, B Besse, G Meurice, N Cagnard, ... Journal for Immunotherapy of Cancer 8 (1), 2020 | 35 | 2020 |
| Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology 5 (4): e1071008 B Besse, M Charrier, V Lapierre, E Dansin, O Lantz, D Planchard, ... | 28 | 2016 |
| Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss D Frisone, M Charrier, S Clement, Y Christinat, L Thouvenin, K Homicsko, ... Cancer biology & therapy 21 (3), 197-202, 2020 | 20 | 2020 |
| Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016; 5 (4): e1071008 B Besse, M Charrier, V Lapierre, E Dansin, O Lantz, D Planchard, ... PubMed Abstract| Publisher Full Text| Free Full Text| F1000 Recommendation, 2015 | 15 | 2015 |
| Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab L Thouvenin, M Charrier, S Clement, Y Christinat, JC Tille, M Frigeri, ... Gynecologic Oncology Reports 37, 100787, 2021 | 11 | 2021 |
| MA07. 01 circulating immature neutrophils, tumor-associated neutrophils and dNLR for identification of fast progressors to immunotherapy in NSCLC L Mezquita, P Martin-Romano, E Auclin, B Duchemann, L Cassard, ... Journal of Thoracic Oncology 14 (10), S272-S273, 2019 | 8 | 2019 |
| The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients L Mezquita, E Auclin, M Charrier, R Ferrara, JR Masip, D Planchard, ... Annals of Oncology 28, v473, 2017 | 7 | 2017 |
| Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients L Mezquita, M Charrier, L Faivre, L Dupraz, B Lueza, J Remon, ... Lung Cancer 112, 10-15, 2017 | 5 | 2017 |
| P3. 02c-065 Neutrophil-To-Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients L Mezquita, M Charrier, E Auclin, M Gion, J Remon, D Planchard, ... Journal of Thoracic Oncology 12 (1), S1315-S1316, 2017 | 5 | 2017 |
| Baseline-derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) to predict the benefit of immune checkpoint inhibitors (ICI) in advanced non-small cell … L Mezquita, E Auclin, R Ferrara, C Audigier-Valette, L Tessonnier, ... Journal of Clinical Oncology 35 (15_suppl), 9089-9089, 2017 | 4 | 2017 |
| Automated detection of arm-level alterations for individual cancer patients in the clinical setting Y Christinat, P Chaskar, S Clément, L Ho, M Charrier, T McKee, ... The Journal of Molecular Diagnostics 23 (12), 1722-1731, 2021 | 3 | 2021 |
| 7P Comparison of the clinical utility of two different size next generation sequencing (NGS) gene panels for solid tumours B Özdemir, M Charrier, CL Gerard, A Wicky, M Caikovski, M Cuendet, ... Annals of Oncology 31, S1219, 2020 | 3 | 2020 |
| HLA-A2 and immune checkpoints inhibitors in advanced non-small cell lung cancer (NSCLC) patients L Mezquita, M Charrier, J Lahmar, J Remon, MV Bluthgen, F Facchinetti, ... Annals of Oncology 27 (suppl 6), 1223P, 2016 | 2 | 2016 |
Jordi RemonHospital de Mataró在 csdm.cat 的电子邮件经过验证
